Search Results
Aug 07, 2026, 08:30 ET Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-'1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity.
More news about: Neurocrine Biosciences, Inc.
Aug 06, 2026, 16:05 ET MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor
More news about: MetaVia Inc.
Aug 06, 2026, 07:15 ET Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston
all 50 U.S. states.Expanded its portfolio to more than 45 physician-supervised healthcare products and programs, including GLP-1s, peptides, hormone health, weight management, wellness, diagnostics, and preventative healthcare offerings.Recently provided a business update
More news about: Hydreight Technologies Inc.
Aug 06, 2026, 06:30 ET BD Reports Third Quarter Fiscal 2026 Financial Results
safety.BioPharma Systems:Announced a collaboration with EMS, one of Brazil's leading pharmaceutical companies, to expand access to GLP-1 therapies through a semaglutide launch utilizing BD's Vystra™ Injection Pen platform to support consistent, reliable self-injection for patients
More news about: BD (Becton, Dickinson and Company)
Aug 05, 2026, 20:10 ET Menu-Order AI Names Dr. Leigh-Anne Dale as Founding Medical Advisor
Physician specializing in Transplant Nephrology, will support educational initiatives for GLP-1 users, physicians and clinicians.BOSTON, Aug. 5, 2026 /PRNewswire/
More news about: MENU - ORDER AI
Aug 05, 2026, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
2026 Results for three Phase III clinical trials expected by end of 2026: NEREUS™ (tradipitant) in vomiting in GLP-1, VQW-765 in social anxiety disorder HETLIOZ® (tasimelteon) in delayed sleep phase disorder
More news about: Vanda Pharmaceuticals Inc.
Aug 05, 2026, 08:00 ET Revolune and Propath UK Bring Service-Backed Multiplex immunofluorescence Workflows to Biopharma Customers
With more than 35 years of experience supporting translational research, biomarker development and regulated studies, Propath delivers high-quality, GLP and GCP-compliant services for both preclinical and clinical trial [email protected]
More news about: Revolune
Aug 05, 2026, 06:45 ET Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
announcement)Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials (
More news about: Eli Lilly and Company
Aug 05, 2026, 06:30 ET CVS HEALTH CORPORATION REPORTS STRONG SECOND QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE
appropriate, prescribe GLP-1 therapy. In addition, CVS Pharmacy participates in the Centers for Medicare & Medicaid Services Medicare GLP-1 Bridge program, which runs through December 31, 2027. Eligible Medicare beneficiaries can access certain GLP-1 medications for $50
More news about: CVS Health
Aug 05, 2026, 06:25 ET CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications
consumer access to prescription drugs is easier to deliver. For GLP-1s, it's simple for eligible patients to use our scheduler technology to connect with licensed clinicians 24 hours a day through MinuteClinic®, access GLP-1 medications through CVS Pharmacy®, receive personalized pharmacist
More news about: CVS Health
Aug 05, 2026, 03:00 ET Revolune and Propath UK Bring Service-Backed Multiplex immunofluorescence Workflows to Biopharma Customers
With more than 35 years of experience supporting translational research, biomarker development and regulated studies, Propath delivers high-quality, GLP and GCP-compliant services for both preclinical and clinical trial [email protected]
More news about: Revolune
Aug 05, 2026, 02:00 ET Revolune und Propath UK bieten ihren Kunden aus der Biopharma-Branche servicegestützte Workflows für die Multiplex-Immunfluoreszenz an
35 Jahren Erfahrung in der Unterstützung der translationalen Forschung, der Biomarker-Entwicklung und regulierter Studien bietet Propath hochwertige, GLP- und GCP-konforme Dienstleistungen sowohl für präklinische als auch für klinische Studienprogramme an.
More news about: Revolune
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
133)MariTide is a differentiated antibody-peptide conjugate that activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MariTide's long-acting design supports starting
More news about: Amgen
Aug 04, 2026, 15:08 ET Restore Hyper Wellness Encourages Americans to "Know Your Number" During National Wellness Month
Wellness Month initiatives.Clients who purchase an NAD+/NR Plan may receive a complimentary Fog Lifter IV, while those who purchase a GLP-1 Plan may receive a complimentary Lose It IV. These offers are available to eligible new and current clients and members. All medical plans and services
More news about: Restore Hyper Wellness
Aug 04, 2026, 14:00 ET LifeSpeak Appoints Neil King as Chief Executive Officer
without surveys or forms. The platform is configurable to whichever cost drivers an organization faces, including MSK, GLP-1, cardiometabolic health, mental health, and caregiving. It runs as a standalone member experience, embedded in a product a customer already owns,
More news about: LifeSpeak Inc.
Aug 04, 2026, 13:10 ET BluePill Launches World's First Marketplace to Recruit Synthetic Respondents: 1,000+ AI Twins of Real Buyers
data, that any brand can now talk to directly — live for the breakfast foods category. Pick the consumers you want — cereal brand loyalists, GLP-1 users, price-sensitive granola parents — the way you'd specify a sample from a panel vendor, then chat with them, survey them, or test concepts
More news about: BluePill Inc.
Aug 04, 2026, 10:01 ET Energy-Based Aesthetic Devices Market to Hit USD 29.39 Billion by 2036 Growing at 13.2%: Market Decipher
professional aesthetics, and the report's most consequential finding is a demand category that barely existed five years ago: GLP-1-associated skin laxity, a 'GLP-1 face' and body-laxity patient wave that could drive a USD 2 billion procedure opportunity by 2030.
More news about: Market Decipher
Aug 04, 2026, 07:30 ET Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
individual clinical needs, providers determine appropriate treatment pathways, which may include positional therapy, oral appliance therapy, CPAP therapy or GLP-1 treatment when clinically appropriate."Our goal is to connect members with the right care through one coordinated experience," said Lara Dodo,
More news about: DarioHealth Corp.
Aug 04, 2026, 01:25 ET Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa
a key focus for Innogen's overseas commercialization strategy.Efsubaglutide alfa is an innovative, human-derived, ultra-long-acting GLP-1 receptor agonist independently developed by Innogen Pharmaceuticals. It has been approved in Mainland China and Macau for the treatment of type
More news about: Innogen Pharmaceuticals
Aug 03, 2026, 12:48 ET As the GLP-1 Era Reshapes Weight Management, METAbiotics Launches with Science Designed to Support Long-Term Success
weight management and metabolic health. The launch comes as long-term weight maintenance emerges as one of the defining challenges of the GLP-1 era.
More news about: METAbiotics The Akkermansia Company
Aug 03, 2026, 12:00 ET Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599
10,000 genetic variants, flagging pharmacogenomic markers that affect how individuals respond to common medications including statins and GLP-1 receptor agonists, and screening for carrier status in hereditary conditions. The report also covers health-related traits across nutrition, metabolism,
More news about: Human Longevity, Inc.
Aug 03, 2026, 09:00 ET Andrew Ambrosy, Top Heart Doctor, Highlights GLP-1 and Dual GIP/GLP-1 Use for Lowering Risk of Cardiovascular Attack
2026 /PRNewswire/ -- Cardiologist Andrew P. Ambrosy, MD, MPH, today reminded heart patients of the benefits of taking a GLP-1 or dual GIP-GLP-1 inhibitor to reduce their risk of heart disease. These drugs include semaglutide (Wegovy) and tirzepatide (Zepbound). The
More news about: Andrew P. Ambrosy, MD, MPH
Aug 03, 2026, 06:55 ET 歌禮宣佈其GLP-1口服小分子ASC30啟動全球III期臨床研究，並公佈其同類首創口服小分子GLP-1/GIP/胰澱素固定劑量復方制劑的積極臨床前數據
Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralintide類似、強效且對胰澱素具有選擇性的每日一次口服小分子胰澱素受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FD），一款每月一次皮下注射四靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
once-daily oral small molecule GLP-1, a first-in-class once-daily oral small molecule GLP-1/GIP dual agonist FDC (the first tirzepatide-like oral small molecule combination), a first-in-class once-daily oral small molecule GLP-1/GIP/amylin triple agonist FDC (the first
More news about: Ascletis Pharma Inc.
Jul 31, 2026, 07:00 ET Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
validated across multiple clinical and preclinical programs, demonstrating exceptional ocular tolerability and minimal systemic exposure in extensive GLP toxicology studies.About Proliferative Vitreoretinopathy (PVR)Proliferative Vitreoretinopathy (PVR) is the leading cause of surgical
More news about: Ractigen Therapeutics